Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Parkinson’s disease causality and heterogeneity: a proteogenomic view

Sergio Kaiser, Luqing Zhang, Brit Mollenhauer, Jaison Jacob, Simonne Longerich, Jorge Del-Aguila, Jacob Marcus, Neha Raghavan, David Stone, Olumide Fagboyegun, Douglas Galasko, Mohammed Dakna, Bilada Bilican, Mary Dovlatyan, Anna Kostikova, Jingyao Li, Brant Peterson, Michael Rotte, Vinicius Sanz, Tatiana Foroud, Karla Gonzalez, Samantha J. Hutten, Mark Frasier, Hirotaka Iwaki, Andrew Singleton, Ken Marek, Karen Crawford, Fiona Elwood, Mirko Messa, View ORCID ProfilePablo Serrano-Fernandez
doi: https://doi.org/10.1101/2022.03.09.22272131
Sergio Kaiser
1Translational Medicine Department. Novartis Institutes for Biomedical Research. Basel, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luqing Zhang
2Cardiovascular and Metabolism Department. Novartis Institutes for Biomedical Research. Cambridge, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brit Mollenhauer
3Department of Neurology, University Medical Center Göttingen. Göttingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jaison Jacob
2Cardiovascular and Metabolism Department. Novartis Institutes for Biomedical Research. Cambridge, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Simonne Longerich
5Genome and Biomarker Sciences. Merck Exploratory Science Center. Cambridge, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jorge Del-Aguila
5Genome and Biomarker Sciences. Merck Exploratory Science Center. Cambridge, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jacob Marcus
5Genome and Biomarker Sciences. Merck Exploratory Science Center. Cambridge, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Neha Raghavan
5Genome and Biomarker Sciences. Merck Exploratory Science Center. Cambridge, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Stone
6Department of Genetics, Cerevel Therapeutics. Cambridge, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olumide Fagboyegun
6Department of Genetics, Cerevel Therapeutics. Cambridge, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Douglas Galasko
7Department of Neurosciences, University of Southern California, San Diego. La Jolla, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mohammed Dakna
3Department of Neurology, University Medical Center Göttingen. Göttingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bilada Bilican
4Neuroscience Department. Novartis Institutes for Biomedical Research. Cambridge USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mary Dovlatyan
4Neuroscience Department. Novartis Institutes for Biomedical Research. Cambridge USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Kostikova
1Translational Medicine Department. Novartis Institutes for Biomedical Research. Basel, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jingyao Li
4Neuroscience Department. Novartis Institutes for Biomedical Research. Cambridge USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brant Peterson
4Neuroscience Department. Novartis Institutes for Biomedical Research. Cambridge USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Rotte
1Translational Medicine Department. Novartis Institutes for Biomedical Research. Basel, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vinicius Sanz
4Neuroscience Department. Novartis Institutes for Biomedical Research. Cambridge USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tatiana Foroud
8Department of Medical and Molecular Genetics, Indiana University School of Medicine. Indianapolis, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karla Gonzalez
8Department of Medical and Molecular Genetics, Indiana University School of Medicine. Indianapolis, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samantha J. Hutten
9Michael J. Fox Foundation for Parkinson’s Research. New York, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Frasier
9Michael J. Fox Foundation for Parkinson’s Research. New York, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hirotaka Iwaki
10Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health. Bethesda, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew Singleton
10Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health. Bethesda, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ken Marek
11Institute for Neurodegenerative Disorders. New Haven, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karen Crawford
12Laboratory of Neuroimaging, University of Southern California. Los Angeles, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fiona Elwood
4Neuroscience Department. Novartis Institutes for Biomedical Research. Cambridge USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mirko Messa
4Neuroscience Department. Novartis Institutes for Biomedical Research. Cambridge USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mirko.messa@novartis.com
Pablo Serrano-Fernandez
1Translational Medicine Department. Novartis Institutes for Biomedical Research. Basel, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Pablo Serrano-Fernandez
  • For correspondence: mirko.messa@novartis.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Pathogenesis and clinical heterogeneity in Parkinson’s disease (PD) have been evaluated from genetic, pathological, and clinical perspective. Technology allowing for high-throughput proteomic analyses in cerebrospinal fluid (CSF) has opened new opportunities to scrutinize this heterogeneity. This is to date the most comprehensive proteomics profiling in CSF of PD patients and controls, both in terms of subjects (n=1103) and proteins (n=4135).

Combining CSF aptamer-based proteomics with genetics across all samples we determined the protein quantitative trait loci (pQTLs) linking genetic variants with protein abundance in CSF. Analyzing pQTLs together with summary statistics from the largest PD genome wide association study (GWAS) led us to identify 68 potential causal proteins by Mendelian randomization. The top PD causal protein, GPNMB, has colocalization support and has been reported to be upregulated in the substantia nigra of PD patients.

We also examined three subcohorts of PD patients: LRRK2 variant carriers (LRRK2+), GBA variant carriers (GBA+) and idiopathic PD patients, each with their respective controls. The second goal was to identify proteomic differences between PD patients and controls within and between the three subcohorts. Statistical analyses revealed six proteins differentially expressed when comparing GBA+ PD patients with unaffected GBA+ controls, seven proteins when comparing LRRK2+ PD patients with unaffected LRRK2+ controls and 23 proteins when comparing idiopathic PD patients with healthy controls who did not carry any severe PD mutations.

Furthermore a hypothesis-free stratification of idiopathic PD patients based on their proteomic profile revealed two protein modules based on the co-expression network structure. Based on these modules, cluster analysis revealed two patient endotypes for idiopathic PD.

Differences in the CSF proteomic signature between subcohorts and between idiopathic endotypes, as well as causal targets identified using both proteomics and genetics may together influence the way we approach the identification of potential therapeutic targets in PD.

Competing Interest Statement

The study was supported by the Novartis Institutes for Biomedical Research and Merck. Protein measurements were performed at SomaLogic. A.K., B.B., B.P. F.E., J.J., J.L., L.Z., M. Dovlatyan, M.M., M.R., P.S-F., S.K. and V.S. are or have been employees of Novartis; J.J., S.K., M.M. are also stockholders of Novartis. D.S., J.D-A., J.M., N.R. and S.L. are or have been employees of Merck. All other authors have no conflict of interests to declare.

Funding Statement

The study was supported by the Novartis Institutes for Biomedical Research and Merck.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The samples we have used for the study are available in the PPMI repository

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The results of the current study are publicly available on the LONI database and all data produced in the present work are contained in the manuscript

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted March 12, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Parkinson’s disease causality and heterogeneity: a proteogenomic view
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Parkinson’s disease causality and heterogeneity: a proteogenomic view
Sergio Kaiser, Luqing Zhang, Brit Mollenhauer, Jaison Jacob, Simonne Longerich, Jorge Del-Aguila, Jacob Marcus, Neha Raghavan, David Stone, Olumide Fagboyegun, Douglas Galasko, Mohammed Dakna, Bilada Bilican, Mary Dovlatyan, Anna Kostikova, Jingyao Li, Brant Peterson, Michael Rotte, Vinicius Sanz, Tatiana Foroud, Karla Gonzalez, Samantha J. Hutten, Mark Frasier, Hirotaka Iwaki, Andrew Singleton, Ken Marek, Karen Crawford, Fiona Elwood, Mirko Messa, Pablo Serrano-Fernandez
medRxiv 2022.03.09.22272131; doi: https://doi.org/10.1101/2022.03.09.22272131
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Parkinson’s disease causality and heterogeneity: a proteogenomic view
Sergio Kaiser, Luqing Zhang, Brit Mollenhauer, Jaison Jacob, Simonne Longerich, Jorge Del-Aguila, Jacob Marcus, Neha Raghavan, David Stone, Olumide Fagboyegun, Douglas Galasko, Mohammed Dakna, Bilada Bilican, Mary Dovlatyan, Anna Kostikova, Jingyao Li, Brant Peterson, Michael Rotte, Vinicius Sanz, Tatiana Foroud, Karla Gonzalez, Samantha J. Hutten, Mark Frasier, Hirotaka Iwaki, Andrew Singleton, Ken Marek, Karen Crawford, Fiona Elwood, Mirko Messa, Pablo Serrano-Fernandez
medRxiv 2022.03.09.22272131; doi: https://doi.org/10.1101/2022.03.09.22272131

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Neurology
Subject Areas
All Articles
  • Addiction Medicine (160)
  • Allergy and Immunology (413)
  • Anesthesia (90)
  • Cardiovascular Medicine (855)
  • Dentistry and Oral Medicine (159)
  • Dermatology (97)
  • Emergency Medicine (248)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (393)
  • Epidemiology (8550)
  • Forensic Medicine (4)
  • Gastroenterology (383)
  • Genetic and Genomic Medicine (1744)
  • Geriatric Medicine (167)
  • Health Economics (371)
  • Health Informatics (1237)
  • Health Policy (619)
  • Health Systems and Quality Improvement (467)
  • Hematology (196)
  • HIV/AIDS (372)
  • Infectious Diseases (except HIV/AIDS) (10281)
  • Intensive Care and Critical Care Medicine (552)
  • Medical Education (192)
  • Medical Ethics (51)
  • Nephrology (210)
  • Neurology (1670)
  • Nursing (97)
  • Nutrition (248)
  • Obstetrics and Gynecology (325)
  • Occupational and Environmental Health (450)
  • Oncology (926)
  • Ophthalmology (263)
  • Orthopedics (100)
  • Otolaryngology (172)
  • Pain Medicine (112)
  • Palliative Medicine (40)
  • Pathology (252)
  • Pediatrics (534)
  • Pharmacology and Therapeutics (247)
  • Primary Care Research (207)
  • Psychiatry and Clinical Psychology (1764)
  • Public and Global Health (3832)
  • Radiology and Imaging (622)
  • Rehabilitation Medicine and Physical Therapy (319)
  • Respiratory Medicine (520)
  • Rheumatology (207)
  • Sexual and Reproductive Health (165)
  • Sports Medicine (157)
  • Surgery (190)
  • Toxicology (36)
  • Transplantation (101)
  • Urology (74)